司库奇尤单抗治疗坏疽性脓皮病：一例报告。
Pyoderma gangrenosum treated with secukinumab: A case report.
作者信息
McPhie Meghan L, Kirchhof Mark G
机构信息
Department of Medicine, Queen's University, Kingston, ON, Canada.
Division of Dermatology, Faculty of Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
出版信息
SAGE Open Med Case Rep. 2020 Jul 17;8:2050313X20940430. doi: 10.1177/2050313X20940430. eCollection 2020.
Pyoderma gangrenosum is a challenging disease to manage, due in part to the lack of approved treatment therapies. Recently, the emergence of biologic agents has expanded treatment options, with tumour necrosis factor alpha inhibitors being the best supported in the literature. In our report, we present a 50-year-old female with pyoderma gangrenosum who was successfully treated with the anti-interleukin-17 biologic agent, secukinumab, after failing other systemic therapies.
坏疽性脓皮病是一种治疗颇具挑战性的疾病，部分原因是缺乏经批准的治疗方法。近年来，生物制剂的出现拓宽了治疗选择，其中肿瘤坏死因子α抑制剂在文献中得到的支持最多。在我们的报告中，我们介绍了一名50岁患有坏疽性脓皮病的女性，在其他全身治疗失败后，使用抗白细胞介素-17生物制剂司库奇尤单抗成功治愈。
Zotero 插件